The global liver disease treatment market accounted for USD 24.48 billion in 2023 and is expected to reach at USD 45.47 billion by 2034 with a CAGR of 5.79% during the forecast period 2024-2034. Increase in the prevalence of liver diseases among individuals, rising alcohol consumption & poor dietary habits, growing demand for more advanced & effective treatments, government & non-profit organizations are actively raising awareness about this issue, surge in new product launches, and rising approval of innovative treatment options for liver diseases are some of the key factors boosting the market growth.
Rising approval of innovative treatment options for liver diseases is predicted to boost the market growth during the forecast period. "Liver diseases" encompass a range of illnesses that can adversely affect the liver. Cirrhosis may develop as a consequence of liver disease progression, wherein the liver's normal function is impaired as healthy tissue is replaced by scar tissue. If left untreated, liver disease can lead to liver failure and liver cancer, while viral infections such as hepatitis A, B, and C can also contribute to liver damage. Non-alcohol-related fatty liver disease (NAFLD) can arise from excessive fat consumption. For instance, in March 2024, Madrigal Pharmaceuticals, Inc. disclosed that the U.S. Food and Drug Administration (FDA) has provided accelerated approval for Rezdiffra (resmetirom) for use alongside diet and exercise. This approval is for treating adults with noncirrhotic NASH who have moderate to advanced liver fibrosis, corresponding to stages F2 to F3 fibrosis.
By treatment type, antiviral drugs was the highest revenue-grossing segment in the global liver disease treatment market in 2023 owing to the growing recognition of the benefits of antiviral drugs, high prevalence of liver diseases caused by viruses such as hepatitis. These diseases highlight the efficacy of antiviral treatments, supported by expanding research demonstrating their effectiveness in therapy. Additionally, immunosuppressant drugs is predicted to grow at the fastest CAGR during the forecast period owing to the rise in the number of patients affected by liver diseases, and increase in approvals granted by regulatory authorities. For instance, in January 2022, Merck obtained conditional approval for its liver cancer treatment drug, Keytruda, following positive results from a second confirmatory study. Keytruda demonstrated a 21% reduction in the risk of death compared to a placebo in patients with hepatocellular carcinoma in Asia.
By disease, hepatitis was the highest revenue-grossing segment in the global liver disease treatment market in 2023 owing to the Alcohol consumption, illicit drug use, and medical errors are on the rise, contributing to an increase in hepatitis cases, and intensified research and development efforts in the healthcare sector. For instance, in January 2022, Madrigal Pharmaceuticals, Inc. released encouraging top-line results from the placebo-controlled, double-blind phase 3 MAESTRO-NAFLD (Non-Alcoholic Fatty Liver Disease) safety trial of Resmetirom. Additionally, autoimmune diseases is predicted to grow at the fastest CAGR during the forecast period owing to the increasing incidence of autoimmune diseases and advancements in research and development efforts.
By end-user, hospitals was the highest revenue-grossing segment in the global liver disease treatment market in 2023 owing to growing presence of intensive care facilities such as ICUs & HDUs, increasing burden of patients with chronic liver disorders, and surge in the introduction of new drugs. For instance, in February 2024, Zydus Lifesciences of India is targeting an initial entry into the United States pharmaceutical market by early 2026 with its first new drug. The company secured fast-track designation from the U.S. FDA for its Saroglitazar medication, intended for the treatment of Primary Biliary Cholangitis (PBC), a chronic inflammatory liver condition. Additionally, ambulatory surgery centers is predicted to boost the market growth during the forecast period owing to the increase in investments aimed at developing infrastructure to improve the distribution of treatments.
North America region is anticipated for the highest revenue share during the forecast period owing to the rising prevalence of liver diseases and surge in the number of clinical trial investigations. For instance, in December 2022, Altimmune, Inc. revealed promising top-line findings from its 24-week trial of Pemvidutide for non-alcoholic fatty liver disease, which included a 12-week extension period. The results indicate the potential for significant reductions in liver fat content and inflammation. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the increasing awareness regarding the various treatment options available, and rise in research and development efforts. For instance, in January 2023, The Phase 2 SEQUOIA clinical study of experimental Fazirsiran for the treatment of liver disease associated with alpha-1 antitrypsin deficiency (AATD-LD) was presented by Takeda and Arrowhead Pharmaceuticals Inc. with top-line results.
This comprehensive research report focuses on the global and regional market size and forecasts from 2023 to 2034.
Rising approval of innovative treatment options for liver diseases is predicted to boost the market growth during the forecast period. "Liver diseases" encompass a range of illnesses that can adversely affect the liver. Cirrhosis may develop as a consequence of liver disease progression, wherein the liver's normal function is impaired as healthy tissue is replaced by scar tissue. If left untreated, liver disease can lead to liver failure and liver cancer, while viral infections such as hepatitis A, B, and C can also contribute to liver damage. Non-alcohol-related fatty liver disease (NAFLD) can arise from excessive fat consumption. For instance, in March 2024, Madrigal Pharmaceuticals, Inc. disclosed that the U.S. Food and Drug Administration (FDA) has provided accelerated approval for Rezdiffra (resmetirom) for use alongside diet and exercise. This approval is for treating adults with noncirrhotic NASH who have moderate to advanced liver fibrosis, corresponding to stages F2 to F3 fibrosis.
By treatment type, antiviral drugs was the highest revenue-grossing segment in the global liver disease treatment market in 2023 owing to the growing recognition of the benefits of antiviral drugs, high prevalence of liver diseases caused by viruses such as hepatitis. These diseases highlight the efficacy of antiviral treatments, supported by expanding research demonstrating their effectiveness in therapy. Additionally, immunosuppressant drugs is predicted to grow at the fastest CAGR during the forecast period owing to the rise in the number of patients affected by liver diseases, and increase in approvals granted by regulatory authorities. For instance, in January 2022, Merck obtained conditional approval for its liver cancer treatment drug, Keytruda, following positive results from a second confirmatory study. Keytruda demonstrated a 21% reduction in the risk of death compared to a placebo in patients with hepatocellular carcinoma in Asia.
By disease, hepatitis was the highest revenue-grossing segment in the global liver disease treatment market in 2023 owing to the Alcohol consumption, illicit drug use, and medical errors are on the rise, contributing to an increase in hepatitis cases, and intensified research and development efforts in the healthcare sector. For instance, in January 2022, Madrigal Pharmaceuticals, Inc. released encouraging top-line results from the placebo-controlled, double-blind phase 3 MAESTRO-NAFLD (Non-Alcoholic Fatty Liver Disease) safety trial of Resmetirom. Additionally, autoimmune diseases is predicted to grow at the fastest CAGR during the forecast period owing to the increasing incidence of autoimmune diseases and advancements in research and development efforts.
By end-user, hospitals was the highest revenue-grossing segment in the global liver disease treatment market in 2023 owing to growing presence of intensive care facilities such as ICUs & HDUs, increasing burden of patients with chronic liver disorders, and surge in the introduction of new drugs. For instance, in February 2024, Zydus Lifesciences of India is targeting an initial entry into the United States pharmaceutical market by early 2026 with its first new drug. The company secured fast-track designation from the U.S. FDA for its Saroglitazar medication, intended for the treatment of Primary Biliary Cholangitis (PBC), a chronic inflammatory liver condition. Additionally, ambulatory surgery centers is predicted to boost the market growth during the forecast period owing to the increase in investments aimed at developing infrastructure to improve the distribution of treatments.
North America region is anticipated for the highest revenue share during the forecast period owing to the rising prevalence of liver diseases and surge in the number of clinical trial investigations. For instance, in December 2022, Altimmune, Inc. revealed promising top-line findings from its 24-week trial of Pemvidutide for non-alcoholic fatty liver disease, which included a 12-week extension period. The results indicate the potential for significant reductions in liver fat content and inflammation. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the increasing awareness regarding the various treatment options available, and rise in research and development efforts. For instance, in January 2023, The Phase 2 SEQUOIA clinical study of experimental Fazirsiran for the treatment of liver disease associated with alpha-1 antitrypsin deficiency (AATD-LD) was presented by Takeda and Arrowhead Pharmaceuticals Inc. with top-line results.
This comprehensive research report focuses on the global and regional market size and forecasts from 2023 to 2034.
Report Scope:
- Base Year: 2023
- Forecast Period: 2024-2034
- Study Coverage
- Market Forecast by Treatment Type, Disease, and End-user
- Market Forecast for 5 Regions and 17+ Countries
- North America (U.S. and Canada)
- Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
- Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
- MEA (South Africa, GCC, Rest of MEA)
- Exhaustive Company Profiles of Top 10+ Major Market Players
Segmentation: Liver Disease Treatment Market Report 2023 - 2034
Liver Disease Treatment Market Analysis & Forecast by Treatment Type 2023 - 2034 (Revenue USD Bn)
- Immunosuppressant Drugs
- Chemotherapy Drugs
- Targeted Therapy
- Anti-Viral Drugs
- Immunoglobulin
- Vaccines
- Others
Liver Disease Treatment Market Analysis & Forecast by Disease 2023 - 2034 (Revenue USD Bn)
- Non-alcoholic Fatty Liver Disease (NAFLD)
- Autoimmune Diseases
- Genetic Disorders
- Hepatitis
- Cancer
- Others
Liver Disease Treatment Market Analysis & Forecast by End-user 2023 - 2034 (Revenue USD Bn)
- Ambulatory Surgery Centers
- Hospitals
- Others
Liver Disease Treatment Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Liver Disease Treatment Market: Treatment Type Estimates & Trend Analysis
8. Liver Disease Treatment Market: Disease Estimates & Trend Analysis
9. Liver Disease Treatment Market: End-user Estimates & Trend Analysis
10. Regional Market Analysis
11. North America Liver Disease Treatment Market
12. Europe Global Liver Disease Treatment Market
13. Asia Pacific Global Liver Disease Treatment Market
14. Latin America Global Liver Disease Treatment Market
15. MEA Global Liver Disease Treatment Market
16. Competitor Analysis
17. Company Profiles
Companies Mentioned
- F. Hoffmann-La Roche Ltd.
- Abbott Laboratories
- Sanofi AG
- Bristol-Myers Squibb Company
- Merck & Co. Inc.
- Endo International PLC
- GlaxoSmithKline PLC
- Alnylam Pharmaceuticals Inc.
- Novartis AG
- Astellas Pharma Inc.
- Takeda Pharmaceutical
- AbbVie Inc
- Gilead Sciences
- Pfizer Inc.
- Provectus Biopharmaceuticals Inc.
